Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway

Cisplatin (DDP) is the first-line chemotherapeutic agent against lung cancer. However, the therapeutic effect of DDP loses over time due to the acquired drug resistance in non-small cell lung cancer (NSCLC) cells. In recent years, the role of the traditional Chinese medicine (TCM) cordycepin (Cor) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Xiao-Zhong, Gao, Ying, Zhao, Hong-Wei, Zhou, Mi, Chen, Dan-Lei, Tao, Lan-Ting, Guo, Wei, Sun, Ling-Ling, Gu, Chu-Ying, Chen, Han-Rui, Xiao, Zhi-Wei, Zhang, Jia-Xing, He, Mei-Fang, Lin, Li-Zhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843937/
https://www.ncbi.nlm.nih.gov/pubmed/33520990
http://dx.doi.org/10.3389/fcell.2020.609285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843937/
https://www.ncbi.nlm.nih.gov/pubmed/33520990
http://dx.doi.org/10.3389/fcell.2020.609285

Ejemplares similares